Outcome after left ventricular assist device exchange
European Journal of Cardio-Thoracic Surgery · 2024
DOI: 10.1093/ejcts/ezae317 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2024. Verfasst von Jaiel Niamat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Heart-Assist Devices, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVES Left ventricular assist device (LVAD) therapy has evolved from a short-term bridge-to-transplant strategy into a long-term and often chronic therapy due to long waiting times for heart transplantation and application as destination therapy. Consequently, patients are at risk of developing complications necessitating LVAD exchange. The aim of this study is to assess patient outcomes after LVAD exchange. METHODS Patients who underwent LVAD exchange between January 2010 and December 2022 were included. Logistic and cox regression analyses were used to identify potential risk factors for short and long-term adverse events, respectively. Survival after exchange was assessed using Kaplan–Meier estimates. RESULTS Sixty-one patients underwent a total of 80 LVAD exchanges. Most frequently observed short-term complications were pulmonary infections (16.3%) and right heart failure (16.3%). Exit-site infections (34.7%) and device malfunctions (25.3%) were the most often observed long-term complications. HeartWare ventricular assist device as index device was associated with a higher risk of right heart failure [hazard ratio 6.42, 95% confidence interval (CI) 1.80–22.90] and respiratory failure (hazard ratio 7.81, 95% CI 1.95–31.23) compared to HeartMate II and HeartMate 3. Survival was 83% (95% CI 75.5–95.3%) at 1 year and 67% (95% CI 53.9–84.7%) at 6 years after exchange. After 5 years, 25.0% was transplanted, 23.8% had undergone a re-exchange and 32.5% was alive without new intervention. CONCLUSIONS Although LVAD exchange can be performed with a relatively low mortality, other post-operative adverse events are common. Patients with the HeartWare ventricular assist device as index device may be at higher risk of developing right heart failure and respiratory failure after exchange.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
- Department of Cardiology, University Medical Center Utrecht, Utrecht, Netherlands.
ORCID-Profile: Jaiel Niamat, Mostafa M Mokhles
Zitieren
APA
Niamat, J., Ramjankhan, F., Van Der Kaaij, N., Gianoli, M., Van Laake, L. W., & Mokhles, M. M. (2024). Outcome after left ventricular assist device exchange. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezae317
Vancouver
Niamat J, Ramjankhan F, Van Der Kaaij N, Gianoli M, Van Laake LW, Mokhles MM. Outcome after left ventricular assist device exchange. European Journal of Cardio-Thoracic Surgery. 2024. doi:10.1093/ejcts/ezae317
BibTeX
@article{Niamat2024,
author = {Niamat, Jaiel and Ramjankhan, Faiz and Van Der Kaaij, Niels and Gianoli, Monica and Van Laake, Linda W and Mokhles, Mostafa M},
title = {Outcome after left ventricular assist device exchange},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2024},
doi = {10.1093/ejcts/ezae317}
}
EUVIMED